RCS - Proteome Sciences - PRM,INmune Bio presenting biomarker discovery data

Proteome Sciences

05/11/2021 06:59

RNS Number : 4286R

Proteome Sciences PLC

05 November 2021

 

 

 

 

 

Reach announcement (non-regulatory)*

 

 

5 November 2021

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Proteome Sciences and INmune Bio to present biomarker discovery data at Clinical Trials in Alzheimer's Disease 2021, Boston

 

November 5th 2021 - London, UK & Boca Raton, USA - Proteome Sciences announces that Dr. Ian Pike, Chief Scientific Officer of Proteome Sciences, will be presenting data from a recent study performed with INmune Bio of Boca Raton, Florida, at the 2021 edition of Clinical Trials in Alzheimer's Disease conference being held in Boston, USA from November 7th to 9th. In this study, Proteome Sciences used its patented TMTcalibrator™ workflow to discover biomarkers supporting the response of Alzheimer's disease patients enrolled in a Phase I clinical study of INmune Bio's XPro1595.

 

Xpro1595 is a novel sTNF antagonist targeting inflammation and related processes associated with Alzheimer's disease and other neurodegenerative conditions. A recently completed Phase I trial showed promising results, including evidence of reduced inflammation and re-myelination in brain white matter obtained through imaging studies. To further support decisions for future clinical studies, INmune Bio contracted Proteome Sciences to deliver an in-depth proteomics analysis of cerebrospinal fluid samples.

 

This analysis discovered multiple peripheral biomarkers consistent with anti-inflammatory action, as well as pathways related to neurodegeneration, neuronal organization, synaptic function and myelination. Most strikingly, it revealed a broad reduction in the phosphorylation of tau protein, which is a common hallmark of Alzheimer's disease, and in particular at the pT217 site which has recently been reported as an important biomarker with strongly increased levels seen in advanced disease. Several of these proteins may be developed for monitoring progression in Phase II clinical studies.

 

Dr. RJ Tesi, CEO, INmune Bio commented "The use of biomarkers to drive clinical development forward in CNS diseases including Alzheimer's disease may be a key to success. The use of Proteome Science's TMTcalibrator™ in CSF of patients treated with XPro has given us new insights into Alzheimer's disease and the effects of XPro therapy."

 

Dr. Ian Pike said "We are delighted that INmune Bio has joined the growing list of customers recognizing the value of our TMTcalibrator™ workflow. The novel combination of diseased tissue with peripheral fluids provides a much deeper and more relevant mapping of biomarkers with utility for strengthening analysis of clinical trial data. We are notably able to profile changes in tau phosphorylation at over 30 sites with very high sensitivity to changes, whilst also covering expression of over 3,500 other proteins. In the short-term, proteomics data can help guide selection of dose and treatment regime for future studies, whilst also providing more readily implemented biomarkers. Longer-term, these biomarkers can be developed for use in the routine clinical management of Alzheimer's disease patients."

 

End.

 

 

 

For further information:

 

Proteome Sciences plc
Dr Mariola Soehngen Chief Executive Officer
Dr Ian Pike, & Chief Scientific Officer

 Tel: +44 (0)20 7043 2116
Allenby Capital Limited (AIM Nominated Adviser & Broker)
John Depasquale / Jeremy Porter
Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.

 

*About Reach announcements

 

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as a regulatory announcement via RNS and not on Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRADZMGMLDVGMZM